EMA Authorised: Welireg (belzutifan) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The European Medicines Agency authorised Welireg (belzutifan) for renal cell carcinoma and von Hippel-Lindau disease, in the EU under conditional approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma
• Von Hippel-lindau Disease

Drugs mentioned

• Welireg (belzutifan)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Renal Cell;von Hippel-Lindau Disease. MAH: Merck Sharp & Dohme B.V.. Decision date: 08/01/2026. Conditional approval